
Home » GE TRIALS FIRST PET IMAGING AGENT TO TRACK BLOOD VESSEL GROWTH IN CANCER
GE TRIALS FIRST PET IMAGING AGENT TO TRACK BLOOD VESSEL GROWTH IN CANCER
GE Healthcare, a division of the General Electric Company has begun a clinical study of a new chemical for use in positron emission tomography (PET) imaging that could be used to monitor angiogenesis, the formation of new blood vessels in tumours.
Medical Technology Business Europe (http://mtbeurope.info/news/2006/606014.htm)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar